Menu
Search
|

Menu

Close
X

Adamis Pharmaceuticals Corp ADMP.OQ (NASDAQ Stock Exchange Capital Market)

1.27 USD
-- (--)
As of Jul 18
Previous Close 1.27
Open --
Volume --
3m Avg Volume 67,930
Today’s High --
Today’s Low --
52 Week High 4.25
52 Week Low 1.17
Shares Outstanding (mil) 31.35
Market Capitalization (mil) 165.38
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
5
FY18
15
FY17
13
FY16
6
EPS (USD)
FY19
-0.188
FY18
-1.000
FY17
-0.624
FY16
-1.288
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
14.52
7.92
Price to Book (MRQ)
vs sector
4.32
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
15.68
14.56
LT Debt to Equity (MRQ)
vs sector
8.36
10.21
Return on Investment (TTM)
vs sector
-68.80
14.49
Return on Equity (TTM)
vs sector
-79.58
15.79

EXECUTIVE LEADERSHIP

Richard Williams
Consultant, Director, Independent Chairman of the Board, Since 2014
Salary: $540,000.00
Bonus: --
Dennis Carlo
President, Chief Executive Officer, Director, Since 2009
Salary: $605,000.00
Bonus: --
Robert Hopkins
Chief Financial Officer, Vice President - Finance, Since 2009
Salary: $318,000.00
Bonus: --
David Marguglio
Senior Vice President, Chief Business Officer and Director, Since 2010
Salary: $328,000.00
Bonus: --
Karen Daniels
Vice President - Operations, Since 2009
Salary: $225,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11682 El Camino Real Ste 300
SAN DIEGO   CA   92130-2092

Phone: +1858.9972400

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

SPONSORED STORIES